Inherited renal cancer

BJU International

Volumn 86, Issue 2, 2000, Pages 155-164

  Turner, K J ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

CLEAR CELL CARCINOMA; FAMILIAL CANCER; GENE MUTATION; HUMAN; INHERITANCE; KIDNEY CANCER; NEPHROBLASTOMA; PRIORITY JOURNAL; REVIEW; VON HIPPEL LINDAU DISEASE;

ANGIOGENESIS INDUCING AGENTS; ANOXIA; CARCINOMA, RENAL CELL; HIPPEL-LINDAU DISEASE; HUMANS; KIDNEY NEOPLASMS; LIGASES; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; PEDIGREE; PROTEINS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN; WILMS TUMOR;

EID: 0033919783     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2000.00702.x     Document Type: Review

References (82)

1. 1 Vogelzang NJ, Stadler W. Kidney cancer. Lancet 1998; 352: 1691-6
2. 2 Zbar B, Tory K, Merino M et al. Hereditary papillary renal cell carcinoma. J Urol 1994; 151: 561-6
3. 3 Zbar B, Glenn G, Lubensky I et al. Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol 1995; 153: 907-12
4. 4 Schmidt L, Duh FM, Chen F et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genet 1997; 16: 68-73
5. 5 Collins ET. Intra-ocular growths (two cases, brother and sister, with peculiar vascular new growth, probably retinal, affecting both eyes). Trans Ophthalmol Soc 1894; 14: 141-9
6. 6 von Hippel E. Ueber eine sehr seltene Erkrankung der Nethaut. Graefes Arch Ophthalmol 1904; 59: 83-106
7. 7 Lindau A. Frage der Angiomatosis retinae und ihrer Hirncomplikation. Acta Ophthalmol (Copenh) 1927; 4: 193-226
8. 8 Knudson Ag Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820-3
9. 9 Knudson Ag Jr, Strong LC. Mutation and cancer: a model for Wilms' tumor of the kidney. J Natl Cancer Inst 1972; 48: 313-24
10. 10 Latif F, Tory K, Gnarra J et al. Identification of the Von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260: 1317-20
11. 11 Stolle C, Glenn G, Zbar B et al. Improved detection of germline mutations in the Von Hippel-Lindau disease tumor suppressor gene. Human Mutation 1998; 12: 417-23
12. 12 Iliopoulos O, Kaelin WG. The molecular basis of Von Hippel-Lindau disease. Mol Med 1997; 3: 289-93
13. 13 Lubensky IA, Gnarra JR, Bertheau P, Walther MM, Linehan WM, Zhuang Z. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in Von Hippel-Lindau disease patients. Am J Path 1996; 149: 2089-94
14. 14 Herman JG, Latif F, Weng Y et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci 1994; 91: 9700-4
15. 15 Maher ER, Kaelin WG. von-Hippel Lindau disease. Medicine 1997; 76: 381-91
16. 16 Kibel A, Iliopoulos O, DeCaprio JD, Kaelin WG. Binding of the von-Hippel Lindau tumour suppressor protein to elongin B and C. Science 1995; 269: 1444-6
17. 17 Kishida T, Stackhouse TM, Chen F, Lerman MI, Zbar B. Cellular proteins that bind the von-Hippel Lindau gene product: Mapping of binding domains and the effect of missense mutations. Cancer Res 1995; 55: 4544-8
18. 18 Lonergan KM, Iliopoulos O, Ohh M et al. Regulation of hypoxia-inducible mRNAs by the Von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol 1998; 18: 732-41
19. 19 Lee S, Neumann M, Stearman R et al. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the Von Hippel-Lindau tumour suppressor gene. Mol Cell Biol 1999; 19: 1486-97
20. 20 Salceda S, Caro J. Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions: its stabilization by hypoxia depends upon redox-induced changes. J Biol Chem 1997; 272: 22642-7
21. 21 Spataro V, Norbury C, Harris AL. The ubiquitin-proteasome pathway in cancer. Br J Cancer 1998; 77: 448-55
22. 22 Tyers M, Rottapel RVHL. A very hip ligase. Proc Natl Acad Sci USA 1999; 96: 12230-2
23. 23 Gorospe M, Egan JM, Zbar B et al. Protective function of Von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells. Mol Cell Biol 1999; 19: 1289-3000
24. 24 Ohh M, Yauch RL, Lonergan KM et al. The Von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998; 1: 959-68
25. 25 Ruoslahti E. Integrins. J Clin Invest 1991; 87: 1-5
26. 26 Hynes R. Integrins: versatility, modulation, and signalling in cell adhesion. Cell 1992; 69: 11-25
27. 27 Pasqualini R, Bourdoulous S, Koivunen E, Woods VJ, Ruoslahti E. A polymeric form of fibronectin has antimetastatic effects against multiple tumor types. Nat Med 1996; 2: 1197-203
28. 28 Lieubeau-Teillet B, Rak J, Jothy S, Iliopoulos O, Kaelin W, Kerbel RS. Von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumour spheroids. Cancer Res 1998; 58
29. 29 Jones A, Fujiyama C. Angiogenesis in urological malignancy: prognostic indicator and therapeutic target. BJU Int 1999; 83: 553-6
30. 30 Harris AL. Antiangiogenesis for cancer therapy. Lancet 1997; 349: 13-5
31. 31 Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270: 1230-7
32. 32 Maxwell PH, Dachs GU, Gleadle JM et al. Hypoxia-inducible-factor-1 modulates gene expression in solid tumours and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997; 94: 8104-9
33. 33 Iliopoulos O, Levy AP, Jiang C, Kaelin WG, Goldberg MA. Negative regulation of hypoxia-inducible genes by the Von Hippel-Lindau protein. Proc Natl Acad Sci USA 1996; 93: 10595-9
34. 34 Maxwell PH, Wiesener MS, Chang G-W et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-5
35. 35 Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W. The Von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 1999; 13: 1822-33
36. 36 Thrash-Bingham CA, Tartof KD, aHIF. a natural antisense transcript overexpressed in human renal cancer and during hypoxia. J Natl Cancer Inst 1999; 91: 143-51
37. 37 Neckers LM. aHIF: the missing link between HIF-1 and VHL. J Natl Cancer Inst 1999; 91: 106-7
38. 38 Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, Sukhatme VP. The Von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 1997; 17: 5629-39
39. 39 Ananth S, Knebelmann B, Gruning W et al. Transforming growth factor beta 1 is a target for the Von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res 1999; 59: 2210-6
40. 40 Knebelmann B, Ananth S, Cohen HT, Sukhatme VP. Transforming growth factor alpha is a target for the Von Hippel-Lindau tumor suppressor. Cancer Res 1998; 58: 226-31
41. 41 Pause A, Lee S, Lonergan KM, Klausner RD. The Von Hippel-Lindau tumour suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci USA 1998; 95: 993-8
42. 42 Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72: 1-22
43. 43 Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ, Andreasen P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990; 50: 6827-9
44. 44 Los M, Zeamari S, Foekens JA, Gebbink MFBG, Voest EE. Regulation of the urokinase-type plasminogen activator system by the Von Hippel-Lindau tumor suppressor gene. Cancer Res 1999; 59: 4440-5
45. 45 Tureci O, Sahin U, Vollmar E et al. Human carbonic anhydrase XII. cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cancers. Proc Natl Acad Sci USA 1998; 95: 7608-13
46. 46 Ivanov SV, Kuzmin I, Wei MH et al. Down regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type Von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 1998; 95: 12596-601
47. 47 Cohen AJ, Li FP, Berg S et al. Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med 1979; 301: 592-5
48. 48 Kovacs G, Brusa P, De Riese W. Tissue-specific expression of a constitutional 3:6 translocation: development of multiple bilateral renal-cell carcinomas. Int J Cancer 1989; 43: 422-7
49. 49 Schmidt L, Li F, Bron RS, ALE.. Mechanism of tumourigenesis of renal carcinomas associated with the constitutional 3:8 translocation. Cancer J Sci Am 1995; 1: 191-5
50. 50 National Wilms' Tumor Study Group. Wilms' tumor. Status report 1990. J Clin Oncol 1991; 9: 877-87
51. 51 Matsunaga E. Genetics of Wilms' tumor. Hum Genet 1981; 57: 231-46
52. 52 Call KM, Glaser T, Ito CY et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumour locus. Cell 1990; 60: 509-20
53. 53 Little M, Holmes G, Walsh P. WT1: what has the last decade told us? Bioessays 1999; 21: 191-2 02
54. 54 Varanasi R, Bardeesy N, Ghahremani M et al. Fine structure analysis of the WT1 gene in sporadic Wilms tumors. Proc Natl Acad Sci USA 1994; 91: 3554 -8
55. 55 Madden SL, ALE. Transcriptional repression mediated by the WT1 Wilms' tumour gene product. Science 1991; 253: 1550-3
56. 56 Miyagawa K, Kent J, Moore A et al. Loss of WT1 function leads to ectopic myogenesis in Wilms' tumor. Nature Genet 1998; 18: 15-7
57. 57 Drummond IA, Madden SL, Rohwer NP, Bell GI, Sukhatme VP, Rauscher FJ. Repression of the insulin like growth factor II gene by the Wilms tumor suppressor WT1. Science 1992; 257: 674-8
58. 58 Nichols KE, Re GG, Yan YX, Garvin AJ, Haber DA. WT1 induces expression of insulin-like growth factor 2 in Wilms' tumor cells. Cancer Res 1995; 55: 4540-3
59. 59 Werner H, Shen-Orr Z, Rauscher FJ, Morris JF, Roberts CT, LeRoith D. Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol Cell Biol 1995; 15: 3516-22
60. 60 Englert C, Hou X, Maheswaran S et al. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J 1995; 14: 4662-75
61. 61 Davies R, Moore A, Schedl A et al. Multiple roles for the Wilms' tumor suppressor, WT1. Cancer Res 1999; 59 (Suppl): 1747-51
62. 62 Maheswaran S, Park S, Bernard A et al. Physical and functional interaction between WT1 and p53 proteins. Proc Natl Acad Sci USA 1993; 90: 5100-4
63. 63 Johnstone RW, See RH, Sells SF et al. A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol Cell Biol 1996; 16: 6945-6
64. 64 Johnstone RW, Wang J, Tommerup N, Vissing H, Roberts T, Shi Y. Ciao 1 is a novel WD40 protein that interacts with the tumor suppressor protein WT1. J Biol Chem 1998; 273: 10880-7
65. 65 Maheswaran S, Englert C, Zheng G et al. Inhibition of cellular proliferation by the Wilms' tumor suppressor, WT1, requires association with the inducible chaperone Hsp70. Genes Dev 1998; 12: 1108-20
66. 66 Nachtigal MW, Hirokawa Y, Enyeart-Van Houten DL, Flanagan JN, Hammer GD, Ingraham HA. Wilms' tumor 1 and Dax-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression. Cell 1998; 93: 445-54
67. 67 Englert C, Maheswaran S, Garvin AJ, Kreidberg J, Haber DA. Induction of p21 by the Wilms' tumor suppressor gene WT1. Cancer Res 1997; 57: 1429-34
68. 68 Mayo M, Wang C, Drouin S et al. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. EMBO J 1999; 18: 3990-4003
69. 69 Ward A. Beckwith-Wiedemann syndrome and Wilms' tumour. Mol Hum Reprod 1997; 3: 157-68
70. 70 Henry I, Bonaiti-Pellie C, Chehensse V et al. Uniparental paternal disomy in a genetic cancer predisposing syndrome. Nature 1991; 351: 665-7
71. 71 Fleming S. Genetics of kidney tumours. Forum 1998; 8: 176-84
72. 72 Ogawa O, Al E. Relaxation of insulin like growth factor II gene imprinting in Wilms' tumour. Nature 1993; 362: 749-51
73. 73 Steenman MJ, Rainier S, Dobry CJ, Grundy P, Horon IL, Feinberg AP. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nature Genet 1994; 7: 433-9
74. 74 Coppes MJ, Egeler RM. Genetics of Wilms' tumor. Sem Urol Oncol 1999; 17: 2-10
75. 75 McDonald JM, Douglass EC, Fisher R, Al E. Linkage of familial Wilms' tumor predisposition to chromosome 19 and two-locus model for the etiology of familial tumors. Cancer Res 1998; 58: 1387-90
76. 76 Kovacs G. Molecular cytogenetics of renal cell tumors. Adv Cancer Res 1993; 62: 89-124
77. 77 Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathological and immunohistochemical study of 105 tumors. Mod Pathol 1997; 10: 537-44
78. 78 Zbar B, Lerman M. Inherited carcinomas of the kidney. Adv Cancer Res 1998; 75: 163-201
79. 79 Koochekpour S, Jeffers M, Wang PH et al. The Von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 1999; 19: 5902-12
80. 80 Weirich G, Glenn G, Junker K et al. Familial renal oncocytoma: clinicopathological study of 5 families. J Urol 1999; 160: 335-40
81. 81 Zambrano NR, Lubensky IA, Merino MJ, Linehan WM, Walther MM. Histopathology and molecular genetics of renal tumours: Toward unification of a classification system. J Urol 1999; 162: 1246-58
82. 82 Torres VE, Bjornsson J, Zincke H. Inherited renal neoplasms. J Nephrol 1998; 11: 229-38